We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current ALBPS market cap is 100.54M. The company's latest EPS is EUR -0.0576 and P/E is -5.90.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -15.68M | -13.94M | -26.82M | -23.27M | -14.33M |
| Net Income | -17.79M | -25.52M | -31.16M | -24.22M | -17.03M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 17.67M | 27.21M | 34.87M | 21.99M | 11.96M |
| Total Liabilities | 25.2M | 24.94M | 29.07M | 23.9M | 15.85M |
| Total Equity | -7.53M | 2.27M | 5.8M | -1.91M | -3.89M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -15.27M | -9.74M | -23.8M | -18.99M | -12.87M |
| Investing | -278k | -12.71M | 12.16M | -17k | 370k |
| Financing | 7.5M | 21.95M | 29.72M | 6.13M | 7.03M |
| Market Cap | 100.54M |
| Price to Earnings Ratio | -5.90 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 18.09 |
| Price to Book Ratio | -25.85 |
| Dividend Yield | - |
| Shares Outstanding | 295.7M |
| Average Volume (1 week) | 22.88k |
| Average Volume (1 Month) | 21.94k |
| 52 Week Change | 4,827.54% |
| 52 Week High | 1.40 |
| 52 Week Low | 0.0021 |
| Spread (Intraday) | 0.02 (6.52%) |
| Company Name | Biophytis |
| Address |
14 avenue de l’opera paris, paris 75001 |
| Website | https://www.biophytis.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
